While CD81 (as well as CD9 and CD63) is not universally present in all EVs, our previous work has shown that preselecting a subpopulation of plasma EVs using CD81 can reproducibly detect ovarian cancer-associated biomarkers using these nano-engineered microfluidic chips30,32. This evidence concerns the gene CD63 and ovarian carcinoma.